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Human accidents with venomous snakes represent an overwhelming public health 19 
problem, mainly in rural populations of underdevelop d countries. Their high incidence and 20 
the severity of the accidents result in 81,000 to 138,000 deaths per year. The treatment is 21 
based on the administration of purified antibodies, produced by hyper immunization of 22 
animals to generate immunoglobulins (Igs), and then obtained by fractionating hyper immune 23 
plasma. The use of recombinant antibodies is an altern ive to conventional treatment of 24 
snakebite envenoming, particularly the Fv fragment, amed the single-chain variable 25 
fragment (scFv). We have produced recombinant single chain variable fragment scFv against 26 
the venom of the pit viper Bothrops asper at high levels expressed transiently and stably in 27 
transgenic plants and in vitro cultures that is reactive to BaP1 (a metalloproteinase from B. 28 
asper venom). The yield from stably transformed plants was significantly (p > 0.05) higher 29 
than the results in from transient expression. In addition, scFvBaP1 yields from systems 30 
derived from stable transformation were: transgenic callus 62 µg/g (± 2); biomass from cell 31 
suspension cultures 83 µg/g (± 0.2); culture medium fro  suspensions 71.75 mg/L (± 6.18). 32 















degradation induced by BnP1 toxins from B. neuwiedi and by Atroxlysin Ia from B. atrox 1 
venoms. In the present work, we demonstrated the pot ntial use of plant cells to produce 2 
scFvBaP1 to be used in the future as a biotechnological alternative to horse immunization 3 
protocols to produce anti-venoms to be used in human therapy against snakebites. 4 
 5 
Key words: Bothrops, Molecular Farming, scFv, BaP1, in vitro plant cultures, heterologous 6 
expression. 7 
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1 - INTRODUCTION 1 
Accidents with snakes represent a public health issue, considering their high incidence 2 
and the severity of their effects. They are considere  to be a neglected problem since they 3 
mostly affect the rural populations in underdevelopd countries from tropical areas such as 4 
Asia, Africa and Latin America (Sachett et al., 2017). According to the World Health 5 
Organization (WHO), epidemiological data on snake envenoming are estimated at between 6 
1.8 and 2.7 million per year, resulting in 81,000 to 138,000 deaths (Laustsen et al., 2018). In 7 
South America, most of the envenoming events are caused by snakes of the genus Bothrops, 8 
namely, B. asper and B. atrox being included in the group of species with high medical 9 
importance (Gois et al., 2017). 10 
At present, passive immunotherapy is the sole availble treatment against ophidian 11 
accidents. The treatment is based on the administration of purified antibodies, produced by 12 
hyper immunization of animals, generally horses, with snake venoms (WHO, 2012). These 13 
anti-venoms are preparations of immunoglobulins (Igs), or Ig fragments such as F(ab)2 or 14 
Fab, obtained by fractionating hyper immune plasma either by treatment with caprylic acid to 15 
obtain whole IgG preparations (Gutiérrez et al., 2005) or by enzymatic digestion followed by 16 
ammonium sulfate precipitation and chromatographic steps to obtain IgG fragments (WHO, 17 
2010). 18 
Anti-venoms are generally very efficient for neutralizing the most relevant systemic 19 
effects of snakebite envenoming. Therapeutic hindraces may be due to early onset of these 20 
effects, as well as to poor distribution of the Igs and their fragments to the local tissues where 21 
venom is injected (Gutiérrez et al., 1998). Furthermore, administration of anti-venom may be 22 
associated, in a variable percentage of cases, with early and late adverse reactions to the 23 
heterologous proteins (León et al., 2013). 24 
An alternative to conventional treatment of snakebite envenoming is the use of 25 
recombinant monoclonal antibodies. Costs of production in CHO cultivation methods were 26 
compared leading economical basis to make a decision n which platform the anti-venom 27 
production should be built on (Lausten et al., 2017). The scFv antibody is another form of 28 
recombinant antibody for envenoming treatment (Lausten et al 2016a). Such molecules 29 
presents several distinctive features when compared to the whole antibody, such as higher 30 















immunocomplexes formation (Azzazy and Highsmith, 2002; Zhang et al., 2014; Yu et al., 1 
2014). 2 
Castro et al. (2014) has described the generation of a recombinant scFv against BaP1 3 
(scFvBaP1) from the venom of the pit viper B. asper, a medically important species in Central 4 
America and regions of South and North America. BaP1 is an abundant P-I snake venom 5 
metalloproteinase (SVMP) in the venom of B. asper. This toxin plays a relevant role in the 6 
associated local tissue damage. The scFvBaP1 was produced from the mRNA isolated from 7 
the BaP1-8 monoclonal antibody producing cells (MABaP1-8), expressed in Escherichia coli 8 
cytoplasm, and possesses neutralizing activities similar to those of the original monoclonal 9 
antibody. In this respect, the fragment was able to recognize the Bap1 toxin present in the 10 
venom of B. asper and neutralize its hemorrhagic, fibrinolytic, myotoxic and displayed pro-11 
inflammatory properties (Castro et al., 2014). However, the main disadvantage of that 12 
scFvBaP1 was its low yield, which made its large-scale pharmaceutical production unfeasible. 13 
Plant systems stand as an alternative platform to produce pharmaceutical interest 14 
proteins. When compared to other recombinant protein production systems, plants should be 15 
highlighted due to some advantages, such as easy genetic manipulation, high biomass yields, 16 
post-translational modifications, low production cost, and possibility of production scheduling 17 
through the use of industrial bioreactors (Moussavou et al., 2015; Yao et al., 2015; Juarez et 18 
al., 2016; Besufekad; Malaiyarsa, 2017), although the glycosylation patterns still are a 19 
challenge to be overcome for therapeutic uses (Monter -Morales et al., 2017). An interesting 20 
remark is that the first plant-made therapeutic drug for human use was approved by the Food 21 
and Drug Administration (FDA) in 2012 (Fox, 2012) and that over 16 plant-manufactured 22 
proteins in phase I, II, and III clinical trials are in progress (Sack et al 2015). The venom of 23 
the snake B. asper was successfully used to transiently produce a cocktail of antibodies in a N. 24 
benthamiana based model, a more in depth preclinical trial should be done before its use as a 25 
biopharmaceutical (Julve Parrenõ et al., 2018). Although the plantibody technology would be 26 
far to be commercially viable its potential have being demonstrated. 27 
Herein we describe high production levels of a recombinant single chain antibody 28 
fragment (scFv) deduced and modified from scFvBaP1 (Castro et al., 2014), expressed 29 
transiently and stably in transgenic plants and in vitro cultures (callus and suspension cells). 30 















those of the original scFvBaP1 antibody. In addition t  its potential, we propose its use as a 1 
molecular tool to assess function of SVMP present in venoms of different snakes. 2 
 3 
2 - MATERIALS AND METHODS 4 
2.1 - Venoms and enzymes 5 
The Herpetology Laboratory of Instituto Butantan provided Bothrops neuwiedi and B. atrox 6 
venoms. The venoms corresponded to pools obtained from many specimens and were 7 
lyophilized and stored at -20°C. The SVMPs BnP1 and Atroxlysin Ia were purified as 8 
previously described by Baldo et al. (2008) and by Freitas-de Sousa et al. (2017). 9 
 10 
2.2 - Cloning the expression vector 11 
We used the amino acid sequence of the fragment scFvBaP1 (Castro et al., 2014) as 12 
template to optimize the nucleotide sequence by revers  genetics for its expression in 13 
Nicotiana benthamiana. We used the optimization tool in Integrated DNA Technologies 14 
(IDT- https://www.idtdna.com/site) to determine the coding sequence and digestion sites. 15 
After the synthesis, the fragment was digested withthe restriction enzymes NcoI and XhoI and 16 
cloned into the pENTR4® vector (Invitrogen). The ligation product was inserted by 17 
electroporation into Escherichia coli Top 10 One Shot and the transformed cells were selected 18 
with 50mg/L kanamycin. The assembly of the expression vector occurred from the LR 19 
cloning of the target vector pK7WG2D with the cloning vector, in the presence of the enzyme 20 
LR clonase (Invitrogen) selected under 50mg/L of spectinomycin in E. coli top 10.  21 
 22 
2.3 - Transient Expression  23 
For transient expression of the fragment, we used 6 week-old N. benthamiana plants, 24 
cultivated in plastic vessel filled with a mixture of autoclaved substrate Plantmax ® and sand 25 
(1:1) placed in growing chamber at 25 ± 2°C under a 16 h photoperiod. 26 
The Agrobacterium GV3101 strain was grown in Lysogeny Broth (LB) medium (5 27 
mL), the expression vector was inserted in Agrobacterium tumefaciens GV3101 and 28 















The pre inoculum was maintained at 28° C under agitation of 210 rpm for 24 h. 100 µl of 1 
bacterial suspension was transferred to 7.5 ml of LB medium containing the appropriate 2 
antibiotics plus acetosyringone 20 µM and MES 10 mM, pH 5.6. The same procedure was 3 
performed with A. tumefaciens EHA101 transformed with plasmid pPZP212 containing the 4 
anti-silencer TCV-CP (capsid protein from Turnip Crinkle Virus). Bacterial suspensions were 5 
centrifuged at 5,000 rpm for 15 minutes at room temp rature. The pellet was then suspended 6 
in 20 mL of MMA medium (5 g/L) + MES (1.95 g/L), sucrose (20 g/L), acetosyringone (200 7 
µM), pH = 5.6 incubated at 28o C during 3 h without stirring until they reached O.D600 (0.4-8 
0.8). Subsequently, N. benthamiana leaves were infiltrated with that suspension using 1 ml 9 
syringes. The leaves were collected between 3-9 days post agroinfiltration (dpi), and the 10 
expression of the GFP reporter gene was monitored under UV illumination at 480 nm. 11 
Expression of the scFvBaP1 fragment was detected by Dot Blotting immunoassay using the 12 
rabbit primary antibody anti-HIS (1:1000). 13 
 14 
2.4 - Stable Transformation  15 
In order to achieve the stable transformation, N. benthamiana leaf explants from in 16 
vitro propagated plants were co-cultivated with agrobacteria suspension. Briefly, the A. 17 
tumefaciens GV3101 strain was grown in LB medium (5 mL), contai ing the expression 18 
vector as previously described. Then, the pre inoculum was maintained at 28 °C under 19 
agitation of 150 rpm for 16 h. Finally, the bacterial suspension was adjusted to O.D600 0.6 and 20 
was co-cultivated with N. benthamiana leaves during 15 minutes in MS liquid medium 21 
according to the protocol described by Hallwass et al. (2014). Afterwards, to select the cells 22 
that have received the transgene, we used a selection medium composed by 4.4 g/L of 23 
Murashige & Skoog Medium (MS) (Sigma basal medium with Gamborg vitamins) 24 
(Murashige and Skoog, 1962), 20 g/L glucose, 7 g/L agar, and 50 mg/L of Kanamycin, 1mg/L 25 
of Benzyl amino purine (BAP) at pH 5.8 during 28 days when the transgenic the shoots 26 
emerged. These shoots were transferred to rooting media (MS without growth regulators plus 27 
50 mg/L of Kanamycin) and propagated in vitro. 28 
 29 















Total DNA was extracted from the leaves of plants that survived and were rooted on 1 
selection media, based on the protocol described by CTAB modified method (Porebski et al., 2 
1997). In order to confirm the stable transformation of N. benthamiana with the scFvBaP1 3 
gene, a polymerase chain reaction was performed using the enzyme Easy Taq DNA 4 
polymerase (LGC Biotechnology), according to the manuf cturer's recommendations. The 5 
primers used for fragment amplification were, respectiv ly, F 5 6 
'TACCCGGGGATCCTCTAGAG and R 5'CGGCCGCACTAGTGATACA flanking transfer-7 
DNA border. 8 
 9 
2.6 - Callus induction and cell suspensions 10 
Leaf explants of 1cm2 from three transgenic plants lineages were placed in Petri plates 11 
containing 20 mL of MS medium (4.4 g/L MS basal medium, 30 g/L sucrose and 7 g/L Agar) 12 
supplemented with 0.5 mg/L 2,4- dichlorophenoxyacetic acid (2,4-D) and 0.2 mg/L kinetin to 13 
induce callus development. The explants were sub-cultured to fresh media every 14 days 14 
during six weeks. The plates were kept in a growing room at 25oC ± 2, under a photoperiod of 15 
16h. After six weeks of culture, 100 mg from each friable calli were separately transferred to 16 
250 mL Erlenmeyer containing 50 mL of the same culture medium used for callus induction 17 
but without agar. The suspensions were maintained i a shaker table at 120 rpm for 8 days, at 18 
the same temperature and light conditions described fore. Then, each suspension in 19 
triplicate were collected and centrifuged for 10 minutes at 2,000, 4 °C to obtain the fractions 20 
(precipitate and supernatant) that were weighted and separated for further protein analysis and 21 
productivity. 22 
 23 
2.7 - Purification of the recombinant scFvBaP1  24 
The total protein of the extract obtained from the infiltrated leaves were concentrated 25 
using the concentration column Amicon®Ultra (Millipore), the columns were centrifuged at 26 
4,000 rpm for 30 minutes at 4 °C. After centrifugation, the concentrate was applied in a 27 
HisTrapHP 5mL (GE Healthcare) column. Purification was performed following the 28 
instructions of manufacturers, using for elution a gr dient of imidazole concentration (80 mM, 29 
100 mM, 250 mM, and 500 mM). After standardization of the best imidazole concentration 30 















extract from leaves of transgenic plants; 2. total extract from callus induced from transgenic 1 
plants; 3. total extract from cell suspension biomass (precipitate); 4. total extract from cell 2 
suspension culture medium (supernatant). In order to remove the excess of imidazole used in 3 
the elution, the samples were dialyzed using Amicon® Ultra (Millipore) concentration 4 
columns. The columns were centrifuged in a refrigerated centrifuge (4 ° C) for 20 min / 4,000 5 
rpm. The purified proteins were stored at 4 °C. Theconcentration of proteins obtained in each 6 
of the samples was determined by the Lowry et al. (1951) dosing method. The proteins were 7 
analyzed in SDS – PAGE 10% and their expression was detected by the western blotting 8 
technique using the rabbit primary antibody Anti-His (1:1000). 9 
 10 
2.8 - Ability of scFvBaP1 to recognize SVMPs BnP1, Atroxlysin Ia and whole B. asper 11 
venom, by ELISA  12 
We employed the Enzyme-Linked Immunosorbent Assay (ELISA) in order to evaluate 13 
the specificity of the scFvBaP1 fragment. Polystyrene plates were previously sensitized with 14 
2 µg/mL of B. asper total venom, BnP1 toxin (B. neuwiedi) and Atroxlysin Ia toxin (B. atrox) 15 
and subsequently incubated at 4 °C overnight. Afterwards, they were washed 3 times with 16 
PBS/0.05 % Tween, blocked with 3 % BSA for 2 h at 37°C, and washed again with the same 17 
solution. Then, the scFvBaP1 fragment totalizing 100 µg was added to the wells (2 µg/well) 18 
and the plates incubated for 1h at 37°C. The antige-antibody reaction was detected using 19 
anti-His rabbit peroxidase followed by the substrate ortho-phenylenediamine (OPD) and 20 
H2O2. The reaction was quenched with 50 µL of H2SO4 and the absorbance read at 492 nm in 21 
Varioskan system (Thermo ®). 22 
 23 
2.9 - Neutralization of fibrinolytic activity of BnP1, Atroxlysin Ia and whole B. asper 24 
venom by scFvBaP1 antibodies 25 
Fibrinolytic activity was assayed by the fibrin-plate method as used by Castro et al., 26 
(2014). Briefly, a fibrin agarose gel was prepared by mixing 1 mg/mL solution of human 27 
fibrinogen (Calbiochem) with a pre-heated solution of 2 % agarose in 50 mM of Tris-HCl, pH 28 
7.3, buffer containing 200 mM of NaCl, 50 mM of CaCl2 and 2 U/mL of thrombin. The 29 
samples (5 µg- total venom B. asper, BnP1 toxin, Atroxlysin Ia toxin) were incubated with 30 















wells pierced in the solidified gel. Plates were incubated at 37° C overnight, and then the area 1 
of fibrin hydrolysis was measured. The results were expressed in mm2 of fibrinolytic area.  2 
 3 
2.10 - Statistical analysis 4 
The significance of the differences of two mean values was analyzed by the Student's 5 
t-test. When more than two experimental groups were compared, the significance of the 6 
differences was determined by ANOVA, followed by Tukey test (p values < 0.05 were 7 
considered significant). 8 
 9 
3 - RESULTS 10 
3.1 - Transient expression  11 
The expression of the GFP reporter gene was monitored during nine days being its expression 12 
visible from 3 to 9 days after infiltration (DPI). The leaves infiltrated with the genomic 13 
silencing suppressor (TCV-CP) apparently showed GFPmore green spots (Figure 1 B, D) but 14 
the recombinant protein yield was not different. In the Dot-Blotting immunoassay the 15 
expression of the scFvBaP1 fragment has become detectabl  only at the third day following 16 
the agro-infiltration (Figure 2). The expression of the scFvBaP1 fragment was observed both 17 
in the presence and in the absence of the suppressor TCV-CP. 18 
 19 
3.2 - Stable transformation 20 
The PCR from the regenerated explants demonstrated that the stable transformation of 21 
N. benthamiana was successful (Figure 3). Three transgenic plants (P2, P3 and P4) with 22 
detectable expression were obtained from three diffrent explants of the same transformation 23 
experiment. The transformed plants showed in Western blotting assay from the total extracts 24 
detected the expression of the scFvBaP1 fragment. 25 
The band corresponding to the scFvBap1 fragment were shown at ~ 58kDa, thus 26 
suggesting the formation of dimers during the electrophoresis process (Figure 4). 27 
 28 















A trial for Imidazole purification was carried out (Figure 5). The total yielding of the 1 
scFvBap1 fragment by the agro-infiltration method was 43 µg/g (± 0.7) from agro-infiltrated 2 
fresh leaf seven days post infiltration (dpi). The statistical analysis from the yield of the two 3 
treatments (presence and absence of the gene silencing suppressor TCV-CP) did not show 4 
significant difference (Figure 6). The Western Blotting analysis demonstrated the presence of 5 
the scFvBaP1 fragment in the purified samples, with the band at approximately 58 kDa. The 6 
yield obtained from fresh leaves from transgenic plants was 270 µg/g (± 5) 15 days after sub-7 
culture. The statistical analysis comparing the total production yield of the two production 8 
methods (transient and stable) showed a significant difference (Figure 7). The yield from 9 
stably transformed plants was significantly (p > 0.05) higher than the results in from transient 10 
expression. Additionally, scFvBaP1 yields from systems derived from stable transformation 11 
were: transgenic callus 62 µg/g (± 2); biomass from cell suspension cultures 83 µg/g (± 0.2); 12 
culture medium from suspensions 71.75 mg/L (± 6.18) eight days after culture (Table 1). The 13 
analysis demonstrated that the suspension culture mediu  presented higher scFv yields and 14 
productivity. As expected, the scFvBaP1 protein, after being produced was exported to the 15 
culture medium since the coding sequence was built with the signal sequence 2S2 from 16 
Arabidopsis thaliana that drives the protein to the secretory pathway. 17 
 18 
3.4 - Ability of scFvBaP1 to recognize SVMPs BnP1, Atroxlysin Ia and whole B. asper 19 
venom, by ELISA 20 
The ability of the scFvBaP1 fragment to recognize the venom toxins was demonstrated 21 
by the ELISA assay. As expected, the fragment was capable of recognizing the homologous 22 
BaP1 toxin, present in the total venom of B. asper, as well as the isolated BnP1 and 23 
Atroxlysin Ia toxins, two related P-I-class SVMPs isolated from venoms of other species of 24 
Bothrops snakes: B. neuwiedi and B. atrox, respectively. Greater recognition was observed for 25 
the BnP1 toxin, as shown in Figure 8. 26 
 27 
3.5 - Neutralization of enzymatic activity of BnP1, Atroxlysin Ia and whole B. asper 28 
venom by scFvBaP1 antibodies 29 
After the incubation, the scFvBap1 fragment was able to neutralize the fibrin 30 















fibrinolysis caused by the homologous BaP1 toxin, BP1 toxins of B. neuwiedi and by 1 
Atroxlysin Ia (ATX) from B. atrox venoms. By scoring the halos, we demonstrated that the 2 
scFvBaP1 fragment was stable for 24 hours, not allowing the expansion of the halos 3 
measured. Moreover, when scFvBaP1 was applied separat ly, the fragment did not cause any 4 
type of damage to the fibrin, also showing no signif cant differences in relation to the control 5 
(Figure 9). 6 
 7 
4 - DISCUSSION 8 
BaP1 is an enzyme that comprises approximately 10% of B. asper venom from the 9 
Pacific region of Costa Rica (Alape-Giron et al., 2009). BaP1 has low systemic toxicity 10 
(Escalante et al., 2004), but exerts significant loca  tissue damage associated with 11 
hemorrhage, myonecrosis (Rucavado et al., 1995), dermonecrosis and blistering, pain 12 
(Fernandeset al., 2007), and inflammation (Fernandes et al., 2006). Anti-venoms are relatively 13 
inefficient for controlling the extent of local tissue damage, including local hemorrhage and 14 
myonecrosis (Gutiérrez et al., 1998; Otero-Patino, 2009). This is likely to depend on several 15 
factors, such as rapid development of local pathology after the bite and poor access of anti-16 
venom antibodies to the affected tissues. Thus, neutralization of venom-induced local tissue 17 
damage remains one of the most difficult challenges to be improved in the management of 18 
viper snakebite envenoming. To this end, the use of recombinant scFv fragments offers a 19 
promising alternative to improve treatment, mainly owing to the pharmacokinetic properties 20 
of such small molecular mass antibody fragments, which enable them to reach extravascular 21 
spaces in the affected tissues much more readily than whole IgG or its fragments. Some recent 22 
studies point to the scFv fragments as promising molecules in the recognition and 23 
neutralization of toxins present in viper snake venoms. Recombinant antibodies are promising 24 
for envenoming treatment since local lesions starts damages at hospital admission, thus 25 
smaller antibodies like scFv, FAB and VHH are able to rapidly reach target tissues such as 26 
neuromuscular junctions so as to neutralize toxins in circulation. Their larger volumes of 27 
distribution allow these smaller fragments to be highly effective (Lausten et al. 2018). Their 28 
potential has been demonstrated in the treatment of lesions caused by snakes (Laustsen et al., 29 
2016; Pessenda et al. 2016). Lee et al. (2016) expressed scFv fragments capable of 30 
recognizing and neutralizing the effects of venoms of Crotalus durissus, Bungarus 31 















use of recombinant molecules in the treatment of ophidian accidents may help to solve this 1 
neglected public health problem. According to the author, such molecules tend to have a 2 
lower production cost compared to conventional antibod es and can be expressed in easily 3 
controllable systems having an effective action in a small amount. 4 
The E. coli-expressed scFvBaP1 fragment, proposed by Castro et al. (2014), was 5 
shown to be effective against BaP1 and BnP1 toxins, isolated from B. asper and B. neuwiedi 6 
venoms, respectively. However, in this expression system scFvBaP1 yields were 280 µg/L of 7 
culture medium, which makes it impossible its use on an industrial scale. Therefore, in this 8 
work, we proposed the plant system as an alternative platform for producing the scFvBaP1 in 9 
which the production reached 8.96 mg/L/day in suspen ion cell culture. 10 
Currently, within the panorama of plant systems, the most efficient platforms for the 11 
production of recombinant antibodies are tobacco leaves, either by transient or stable 12 
expression. The clinical trial using plant made antibodies may be starting a new era in protein 13 
production for pharmaceutical industries (Ma et al, 2015). When produced in leaves N.14 
benthamiana protein yielding shows reduced alkaloid contamination and this plant species 15 
have been accepted by the U. S. Food and Drug Administration (FDA) as a safety system for 16 
antibody production (Stephan et al., 2017). In order to avoid degradation of recombinant 17 
proteins, some strategies have been adopted, such as t e use of signal peptides targeting 18 
proteins to some cellular compartments, such as the apoplast or the endoplasmic reticulum, as 19 
reported by Goulet et al. (2010); Jutras et al. (2015); Robert et al. (2013). In this work, the 20 
recombinant antibodies were directed to the periplasmic space of the cells, in order to reduce 21 
their degradation. The targeting was performed with the addition of a signal peptide to the 22 
expression cassette. The transient expression, monitored for nine days, was detected after 3 23 
dpi, as shown in the study by Pêra and collaborators (2015). The average yield of the 24 
scFvBaP1 fragment by transient expression was 43 µg/g (± 0.7). Some authors, such as 25 
Lacombe and collaborators (2018), reported a lower production of recombinant proteins by a 26 
plant system, which was associated to gene silencing and protein degradation produced by 27 
proteases by host plant (Grosse-Holtz et al., 2018). Another factor to be taken into account is 28 
the mechanism of gene silencing that tends to happen as a form of plant’s response to 29 
infection, and drastically reduces the levels of recombinant protein expression (Rasool et al., 30 
2016). 31 
In an attempt to mitigate gene silencing on scFvBaP1, the TCV-CP viral suppressor 32 















scFvBaP1 fragment. The statistical analysis showed that there were no significant differences 1 
between both treatments. These data are contrary to those reported by Qu et al. (2003) 2 
working with the same viral suppressor. In that study, significant differences were found 3 
when co-infection was performed using viral suppressor . 4 
Transgenic plants (stable-transformed) have shown t be promising and efficient in the 5 
production of proteins of therapeutic interest, including monoclonal antibodies and scFv 6 
fragments (Moussavou et al., 2015; Xu et al., 2016). The transgenic lines that we have 7 
obtained, besides integrating the transgene, were able to express the scFvBaP1 fragment, 8 
demonstrating its potential use as a biological reactor for its production. Many studies report 9 
the use of N. benthamiana species for the production of biopharmaceutical proteins (Marusic 10 
et al., 2016; Niemer et al., 2015; Alkanaimsh et al., 2016). 11 
We obtained a total yield of 270 µg/g of fresh weight leaves (± 5) of scFvBaP1 in 12 
transgenic plants (stable-transformed). That yield was higher than in the transient production 13 
system. Since in the stable transformation the proteins were directed to the periplasmic space 14 
of the cells, they were protected from proteases, culminating in a higher concentration of 15 
proteins. These results demonstrate a greater efficiency of the stable transformation in relation 16 
to the transient expression and suggest a better efficiency of such a system of production, as it 17 
is reported in the review paper by Merlin et al. (2014). Furthermore, another advantage of the 18 
system is the possibility of obtaining cell suspensio  (Yoshikawa, 2016) which not only are 19 
capable large-scale production, but they also guarantee a homogeneous, clean, and less 20 
expensive production, free from the action of interfering secondary metabolites (e.g. 21 
alkaloids) and overcoming the step of extraction from biomass by directing the secretion of 22 
proteins to the culture medium (Muthamilselvan et al., 2016). In this work, we obtained 83 23 
µg/g (± 0.2) of scFvBaP1 in the biomass and 8.96 mg/L/day (± 0.77) in the culture medium. 24 
As the protein concentration in the culture medium was significantly higher (p> 0.05) than the 25 
concentration of proteins found in the biomass, it is clear that the produced antibodies are 26 
being released into the culture medium. 27 
Furthermore, the production yields of this system can be improved by adjusting the 28 
culture conditions, such as culture medium composition, luminosity, CO2 concentration, 29 
among others. These parameters can be adjusted with the use of semi-industrial bioreactors, 30 
which allow controlling the culture conditions over a period of time, optimizing the protein 31 















In summary, we have initially transiently expressed the scFvBaP1 fragment in leaves 1 
of N. benthamina, with a final yield of 43 µg/g (± 0.7) of infiltrated leaf. Additionally, three 2 
transgenic plant lines capable of expressing the scFvBap1 fragment were obtained, totaling a 3 
production yield of 270 µg/g (± 5). 4 
Moreover, its biological activity against BaP1, BnP1 and Atroxlysin Ia toxins was 5 
verified by the ELISA assay. The scFvBaP1 fragment was able to recognize the BaP1 toxin 6 
present in the total venom of B. asper and also the isolated toxins BnP1 and Atroxlysin Ia. 7 
There was a greater affinity between the scFvBaP1 fragment and the BnP1 toxin, which may 8 
be due to the fact that we employed the total venom of B. asper and not the isolated BaP1 9 
toxin, such metalloproteinase corresponds to 10% of the total venom dry weight (Watanabe, 10 
2003). 11 
The ability of the scFvBaP1 fragment to neutralize th fibrinolytic activity of BaP1, 12 
BnP1 and Atroxlysin Ia toxins was also evaluated. Castro et al. (2014) demonstrated the 13 
neutralization of the fibrinolytic activity of the BaP1 toxin by the scFvBaP1 fragment 14 
produced in E. coli. The scFvBaP1 fragment, expressed in plants, not oly recognized and 15 
inhibited the activity of the BaP1 toxin but also was able to recognize and inhibit the action of 16 
BnP1 and Atroxlysin Ia toxins. This recognition of t xins from different species can be 17 
attributed to the high phylogenetic conservation that the metalloproteinases present, as 18 
reported by Tanjoni et al. (2003). According to the authors, the metalloproteinases are 19 
extremely conserved among snake venoms and derive fom common ancestor ADAM 20 
proteins, thus justifying the presence of common epitopes shared amongst different species of 21 
snakes. 22 
Taking our results into account, we may suggest that the scFvBaP1 fragment may be 23 
used not only to inhibit the effects of the snakebite envenoming caused by B. asper, but also 24 
by other snakes. Possibly, such a fragment exhibits polyvalent recognition, thus 25 
demonstrating itself as a promising molecule to be us d in therapy against ophidian accidents. 26 
In conclusion, the plant systems showed a greater efficiency for producing the 27 
neutralizing scFvBaP1 antibody when compared to the prokaryotes production system. 28 
Additionally, the scFvBaP1 fragment was able to recognize and neutralize the fibrinolytic 29 
activity of BaP1, BnP1 and Atroxlysin Ia toxins. That observation demonstrates its potential 30 
uses to produce the antibody for serum therapy in future research and development for pre-31 
clinical trials in cases of envenoming events caused by snakes B. asper, B. neuwiedi and B. 32 















exploring novel therapeutic alternatives for the neutralization of the local tissue damage 1 
induced by SVMPs abundant in venoms of snakes as B. asper, B. neuwiedi and B. atrox. 2 
Herein, we successfully describe the production of high levels of recombinant single chain 3 
antibody fragment – scFv by transgenic plants. Future studies are necessary to test the 4 
therapeutic potential of this scFv antibody in preclini al experimental models. 5 
 6 
5 - REFERENCES 7 
 8 
Alape-Girón A, Flores-Díaz M, Sanz L, Madrigal M, Escolano J, Sasa M, Calvete JJ. Studies 9 
on the venom proteome of Bothrops asper: Perspectives and applications. Toxicon, 10 
2009;54: 938–948. 11 
Alkanaimsh S, Karuppanan K, Guerrero A, Tu AM, Hashimoto B, Hwang MS, Phu ML, 12 
Arzola L, Lebrilla CB, Dandekar AM, Falk BW, Nandi S, Rodriguez RL, McDonald 13 
KA.Transient Expression of Tetrameric Recombinant Human Butyrylcholinesterase in 14 
Nicotiana benthamiana. Front Plant Sci, 2016;7:743. 15 
Azzazy H ME.; Highsmith WE. Phage display technology : clinical applications and recent 16 
innovations. Clin Biochem, 2002;35: 425–445.  17 
Baldo C, Tanjoni I, León IR, Batista IF, Della-Casa MS, Clissa PB, Weinlich R, Lopes-18 
Ferreira M, Lebrun I, Amarante-Mendes GP, Rodrigues VM, Perales J, Valente RH, 19 
Moura-da-Silva AM. BnP1, a novel P-I metalloproteinase from Bothrops neuwiedi 20 
venom: Biological effects benchmarking relatively to jararhagin, a P-III SVMP. Toxicon, 21 
2008;51:54–65.  22 
Besufekad Y, Malaiyarsa P. Production of Monoclonal Antibodies in Transgenic Plants. J 23 
Adv Biol Biotechno, 2017;12:1-8.  24 
Castro JM, Oliveira TS, Silveira CR, Caporrino MC, Rodriguez D, Moura-da-Silva AM, 25 
Ramos OH, Rucavado A, Gutiérrez JM, Magalhães GS, Faquim-Mauro EL, Fernandes I. 26 
A neutralizing recombinant single chain antibody, scFv, against BaP1, A P-I hemorrhagic 27 
metalloproteinase from Bothrops asper snake venom. T xicon, 2014;87: 81–91.  28 
Escalante T, Rucavado A, Kamiguti AS, Theakston RD, Gutiérrez JM. Bothrops asper 29 















induce systemic hemorrhage or coagulopathy. Toxicon, 2004;43: 213-217. 1 
Fernandes CM, Pereira Teixeira Cde F, Leite AC, Gutiérrez JM, Rocha FA. The snake venom 2 
metalloproteinase BaP1 induces joint hypernociception through TNF-a and PGE2-3 
dependent mechanisms. Br. J. Pharmacol., 2007;151:12 4- 261.  4 
Fernandes CM, Zamuner SR, Zuliani JP, Rucavado A, Gutiérrez JM, Teixeira Cde F. 5 
Inflammatory effects of BaP1 a metalloproteinase isolated from Bothrops asper snake 6 
venom: leukocyte recruitment and release of cytokines. Toxicon, 2006;47: 549- 559. 7 
Freitas-de-Sousa LA, Colombini M, Lopes-Ferreira M, Serrano SMT, Moura-da-Silva AM. 8 
Insights into the Mechanisms Involved in Strong Hemorrhage and Dermonecrosis Induced 9 
by Atroxlysin-Ia, a PI-Class Snake Venom Metalloproteinase. Toxins, 2017;9:pii: E239.  10 
Fox JL. First plant-made biologic approved. 2012; Nat Biotech 30:472-472. 11 
Gois PHF, Martines MS, Ferreira D, Volpini R, Canale D, Malaque C, Crajoinas R, 12 
GirardACC, Massola Shimizu MH, Seguro AC. Allopurinol attenuates acute kidney 13 
injury following Bothrops jararaca envenomation. PLoS Neglect Trop D, 14 
2017 ;11:e0006024. 15 
Goulet C, Benchabane M, Anguenot R, Brunelle F, Khalf M, Michaud D. A companion 16 
protease inhibitor for the protection of cytosol-targeted recombinant proteins in plants. 17 
Plant Biotechnol J, 2010;8:142–154. 18 
Grosse-Holz F, Kelly S, Blaskowski S, Kaschani F, Kaiser M, van der Hoorn RAL. The 19 
transcriptome, extracellular proteome and active secretome of agroinfiltrated N. 20 
benthamiana uncover a large, diverse protease repertoire. Plant Biotechnol J. 21 
2018;16(5):1068-1084. 22 
Gutiérrez JM, León G, Rojas G, Lomonte B, Rucavado A, Chaves F. Neutralization of local 23 
tissue damage induced by Bothrops asper (terciopelo) snake venom. Toxicon, 24 
1998 ;36:1529-1538. 25 
Gutierrez, JM., Rojas, E., Quesada, L., Leon, G., Núnez, J., Laing, GD., Sasa, M., Renjifo, 26 
JM., Nasidi, A., Warrell, DA., Theakston, RD., Rojas, G. Pan-African polyspecific 27 
antivenom produced by caprylic acid purification of horse IgG: an alternative to the 28 
antivenom crisis in Africa. Trans. R. Soc. Trop. Med. Hyg. 2005;99, 468e475. 29 
Hallwass M, de Oliveira AS, de Campos Dianese E, Lohuis D, Boiteux LS, Inoue-Nagata 30 















protein (NSM ) triggers a hypersensitive response in Sw-5-containing resistant tomato 1 
lines and in Nicotiana benthamiana transformed withthe functional Sw-5b resistance gene 2 
copy. Mol Plant Pathol. 2014;15:871-880. 3 
Juarez P, Virdi V, Depicker A, Orzaez D. Biomanufacturing of protective antibodies and 4 
other therapeutics in edible plant tissues for oral applications. Plant Biotechnol J, 5 
2016;14:1791-1799. 6 
Julve Parreño JM, Huet E, Fernández-Del-Carmen A, Segura A, Venturi M, Gandía A, Pan 7 
WS, Albaladejo I, Forment J, Pla D, Wigdorovitz A, Calvete JJ, Gutiérrez C, Gutiérrez 8 
JM, Granell A, Orzáez D. A synthetic biology approach for consistent production of plant-9 
made recombinant polyclonal antibodies against snake venom toxins.Plant Biotechnol J, 10 
2018;16:727-736. 11 
Jutras PV, D'Aoust MA, Couture MM, Vézina LP, Goulet MC, Michaud D, Sainsbury F. 12 
Modulating secretory pathway pH by proton channel co-expression can increase 13 
recombinant protein stability in plants. Biotechnol. J. 2015;10:1478–1486. 14 
Lacombe S, Bangratz M, Brizard JP, Petitdidier E, Pagniez J, Sérémé D, Lemesre JL, 15 
Brugidou C. Optimized transitory ectopic expression of promastigote surface antigen 16 
protein in Nicotiana benthamiana, a potential anti-leishmaniasis vaccine candidate. J 17 
Biosci Bioeng, 2018;125:116-123.  18 
Laustsen AH, María Gutiérrez J, Knudsen C, Johansen KH, Bermúdez-Méndez E, Cerni FA, 19 
Jürgensen JA, Ledsgaard L, Martos-Esteban A, Øhlenschlæger M, Pus U, Andersen MR, 20 
Lomonte B, Engmark M, Pucca MB. Pros and cons of different therapeutic antibody 21 
formats for recombinant antivenom development. Toxic n, 2018; 146:151-175. 22 
Laustsen AH, Johansen KH, Engmark M, Andersen MR. Recombinant snakebite antivenoms: 23 
A cost-competitive solution to a neglected tropical disease? PLoS Negl Trop Dis, 2017; 24 
11(2): e0005361. 25 
Laustsen AH, Engmark M, Milbo C, Johannesen J, Lomonte B, Gutiérrez JM, Lohse B. From 26 
Fangs to Pharmacology: The Future of Snakebite Envenoming Therapy, 2016a; Curr 27 
Pharm Des. 2016;22(34):5270-5293. 28 
Laustsen AH, Solà M, Jappe EC, Oscoz S, Lauridsen LP, Engmark M. Biotechnological 29 















Lee CH, Lee YC, Leu SJ, Lin LT, Chiang JR, Hsu WJ, Yang YY. Production and 1 
Characterization of Neutralizing Antibodies against Bungarus multicinctus Snake Venom. 2 
Appl Environ Microbiol, 2016;pii: AEM.01876-1. 3 
León G, Herrera M, Segura Á, Villalta M, Vargas M, Gutiérrez JM. Pathogenic mechanisms 4 
underlying adverse reactions induced by intravenous administration of snake 5 
antivenoms.Toxicon, 2013;76:63-76. 6 
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. The folin by oliverProtein measurement 7 
with the Folin phenol reagent. J Biol Chem, 1951;217: 20–230. 8 
Ma, JKC, Drake PMW; Christou P. The production of recombinant pharmaceutical proteins 9 
in plants. Nat Rev Genet, 2003;4:794–805. 10 
Magy B, Tollet J, Laterre R, Boutry M, Navarre C. Accumulation of secreted antibodies in 11 
plant cell cultures varies according to the isotype , host species and culture conditions. 12 
Plant Biotechnol J, 2014;12:457–467. 13 
Marusic C, Novelli F, Salzano AM, Scaloni A, Benvenuto E, Pioli C, Donini M. Production 14 
of an active anti-CD20-hIL-2 immunocytokine in Nicotiana benthamiana. Plant 15 
Biotechnol J, 2016;14:240-251. 16 
Merlin M, Gecchele E, Capaldi S, Pezzotti M, Avesani L. Comparative Evaluation of 17 
Recombinant Protein Production in Different Biofactories: The Green Perspective. 18 
Biomed Res Int, 2014:136419. 19 
Montero-Morales L, Maresch D, Castilho A, Turupcu A, Ilieva KM, Crescioli S, Karagiannis 20 
SN, Lupinek C, Oostenbrink C, Altmann F, Steinkellnr H. Recombinant plant-derived 21 
human IgE glycoproteomics. J Proteomics, 2017;161:81-87. 22 
Moussavou G, Ko K, Lee JH, Choo YK. Production of monoclonal antibodies in plants for 23 
cancer immunotherapy. Biomed Res Int, 2015:306164.  24 
Murashige T, Skoog F. A revised medium for rapid growth and bloassaym with tobacco tissue 25 
cultures. Physiol Plantarum 1962;15:473-497 26 
Muthamilselvan T, Lee CW, Cho YH, Wu FC, Hu CC, Liang YC, Lin NS, Hsu YH. A 27 
transgenic plant cell-suspension system for expression of epitopes on chimeric Bamboo 28 















Niemer M, Mehofer U, Verdianz M, Porodko A, Schähs P, Kracher D, Lenarcic B, Novinec 1 
M, Mach L. Nicotiana benthamiana cathepsin B displays distintic enzymatic features 2 
which differ from its human relative and aleurain-like proteasis. Biochimie, 2015 ;122: 3 
119-125. 4 
Otero-Patino R. Epidemiological, clinical and therapeutic aspects of Bothrops asper bites. 5 
Toxicon, 2009;54:998-1011. 6 
Pêra FF, Mutepfa DL, Khan AM, Els JH, Mbewana S, van Dijk AA, Rybicki EP, Hitzeroth II. 7 
Engineering and expression of a human rotavirus candid te vaccine in Nicotiana 8 
benthamiana. Virol J, 2015;12: 205.  9 
Pessenda G, Silva LC, Campos LB, Pacello EM, Pucca MB, Martinez EZ, Barbosa JE. 10 
Human scFv antibodies (Afribumabs) against Africanized bee venom: Advances in 11 
melittin recognition. Toxicon, 2016;112:59-67. 12 
Porebski S, Bailey LG, Baum BR. Modification of a CTAB DNA extraction protocol for 13 
plants containing high polysaccharide and polyphenol components. Plant Mol Biol Rep, 14 
1997;15: 8–15. 15 
Qu F; Ren T, Morris TJ. The Coat Protein of Turnip Crinkle Virus Suppresses 16 
Posttranscriptional Gene Silencing at an Early Initiation Step. J Virol, 2003;77, 1:511–17 
522.  18 
Rasool G, Yousaf S, Amin A, Mansoor S and Saeed M. Transient expression of synthetic coat 19 
protein gene of cotton leaf curl burewala virus in tobacco (Nicotiana benthamiana). J 20 
Agric Res, 2016;54:21-34. 21 
Robert S, Khalf M, Goulet MC, D'Aoust MA, Sainsbury F, Michaud D. Protection of 22 
recombinant mammalian antibodies from development-dpendent proteolysis in leaves of 23 
Nicotiana benthamiana. PloS One, 2013;8:e70203. 24 
Rucavado A, Lomonte B, Ovadia M, Gutiérrez JM. Local tissue damage induced by BaP1, a 25 
metalloproteinase isolated from Bothrops asper (Terciopelo) snake venom. Exp Mol 26 
Pathol, 1995;63:186-199. 27 
Sachett JAG, da Silva IM, Alves EC, Oliveira SS, Samp io VS, do Vale FF, Romero GAS, 28 
Dos Santos MC, Marques HO, Colombini M, da Silva AMM, Wen FH, Lacerda MVG, 29 















preventing secondary infection from Bothrops snakebites in the Brazilian Amazon : A 1 
randomized controlled clinical trial. PLoS Neglect Trop D, 2017;11:e0005745. 2 
Sack M, Hofbauer A, Fischer R, Stoger E. The increasing value of plant-made proteins. 2015; 3 
Current Opinion in Biotechnology 32:163-170. 4 
Stephan A, Hahn-Löbmann S, Rosche F, Buchholz M, Giritch A, Gleba Y. Simple 5 
Purification of Nicotiana benthamiana-Produced Recombinant Colicins: High-Yield 6 
Recovery of Purified Proteins with Minimum Alkaloid Content Supports the Suitability of 7 
the Host for Manufacturing Food Additives. 2017, Int J Mol Sci;29:19(1). pii: E95. 8 
Tanjoni I, Butera D, Spencer PJ, Takehara HA, Fernandes I, Moura-da-Silva AM. 9 
Phylogenetic conservation of a snake venom metalloproteinase epitope recognized by a 10 
monoclonal antibody that neutralizes hemorrhagic activity. Toxicon, 2003;42:809-816. 11 
Watanabe L, Shannon JD, Valente RH, Rucavado A, Alape-Girón A, Kamiguti AS, 12 
Theakston RD, Fox JW, Gutiérrez JM, Arni RK. Amino acid sequence and crystal 13 
structure of BaP1 , a metalloproteinase from Bothrops asper snake venom that exerts 14 
multiple tissue-damaging activities. Protein Sci, 2013;12:2273–2281. 15 
WHO. Animal Bites.WorldWealth Organization, Geneva, Switzerland, 2012. 16 
WHO. Guidelines for the Production, Control and Regulation of Snake Antivenom 17 
Immunoglobulins. World Wealth Organization, Geneva, Switzerland, 2010. 18 
Xu J., Towler M., Weathers P.J. (2016) Platforms for Plant-Based Protein Production. 1-19 
40. In: Pavlov A., Bley T. (eds) Bioprocessing of Plant In Vitro Systems. Reference 20 
Series in Phytochemistry. Springer, Cham 21 
Yao J, Weng Y, Dickey A, Wang KY. Plants as Factories for Human Pharmaceuticals: 22 
Applications and Challenges. Int J Mol Sci, 20015;16:28549-28565. 23 
Yoshikawa M. PremicroRNA processing activity in nuclear extracts from Arabidopsis 24 
suspension cells. J Plant Res, 2016;130:75–82. 25 
Yu F, Wang Y, Xiao Y, He Y, Luo C, Duan D, Li C, Xu S, Xiang T. RP215 single chain 26 
fragment variable and single domain recombinant antibodies induce cell cycle arrest at 27 















Zhang L, Crawford F, Yu L, Michels A, Nakayama M, Davidson HW, Kappler JW, 1 
Eisenbarth GS. Monoclonal antibody blocking the recognition of an insulin peptide-MHC 2 














Table 1 – Average of scFvBaP1 yield and productivity by different methods in 
N.benthamiana. Yield is expressed in recombinant purified protein weight/fresh tissue 
weight from different sources, except in the cell suspension culture medium that contain 
only the MS medium with secreted antibody. Productivity is expressed in recombinant 
purified protein weight/fresh tissue weight/day of culture. 
Sample (days after induction) Yield Productivity (days) 
Infiltrated leaves 43 µg/g (± 0.7) 6.1 µg/g/d 
Transgenic plants 270 µg/g (± 5) 18 µg/g/d 
Transgenic callus 62 µg/g (± 2) 4.1 µg/g/d 
Cell suspension biomass 83 µg/g (± 0,2) 10.37 µg/g/d 
















1 – Successful expression of a fibrinolytic inhibitor venom serum in N. benthamiana. 
2 – scFvBAP1 was active agains the metalloproteinas and total venom from 3 snakes 
3 – Higher expression in stable transgenic plants compared to transient expression. 
4 – Liquid culture medium displayed higher scFvBAP1 yield. 
 
